Kuros Biosciences AG

CSBTFOTCHealthcare● Active

$26.00

+$1.25(+5.05%)

Market Cap$1.0B

P/E Ratio—

52W High$42.81

52W Low$24.75

Avg Volume178

Open$25.29

Beta0.70

Overview

Kuros Biosciences AG (CSBTF) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CSBTF · net income · updated Jun 9, 2026

Core profitability metrics

CSBTF · net income · margin · TTM · CAGR

Net income was $2.1M for FY2025 (fiscal year ending 2025-12-31), up 157.0% year-over-year. Net profit margin was 1.8%. Based on available data, Kuros Biosciences AG has been profitable since at least 2015.

FY2025 Net Income$2.1M▲ +157.0% YoY

Trailing 12M (TTM)−$2.1Mtrailing 4 quarters sum

Net Profit Margin1.8%$2.1M ÷ $121.4M

YoY Change+157.0%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2015

▸ FMP /income-statement · Annual · CSBTF net income history · CSBTF profit margin

Annual net income data

CSBTF · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$2.1M▲ +157.0%1.8%$121.4M

FY2024Loss−$3.7M▲ +72.9%-4.9%$75.6M

FY2023Loss−$13.7M▲ +5.9%-40.9%$33.6M

FY2022Loss−$14.6M▼ 93.5%-81.2%$18.0M

FY2021Loss−$7.5M▲ +34.5%-54.6%$13.8M

Net income vs peers (Healthcare)

CSBTF vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Kuros Biosciences AGYOU

CSBTF

$2.1M+157.0%1.8%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Kuros Biosciences AG (CSBTF) reported net income of $2.1M for FY2025 (fiscal year ending 2025-12-31), up 157.0% year-over-year. The net profit margin was 1.8% — meaning the company kept $0.02 of every dollar of revenue as profit.

Based on available data, Kuros Biosciences AG has been profitable since at least 2015. Net income reached a peak of $6.2M in FY2015. Data available for 15 fiscal years.

Kuros Biosciences AG's net profit margin was 1.8% for FY2025, based on the latest annual results.

Investors sometimes search for "Kuros Biosciences AG net worth" — the company's market capitalization is a separate figure from CSBTF net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CSBTF net income · 5 questions

Kuros Biosciences AG is profitable. The company reported net income of $2.1M for FY2025, a net profit margin of 1.8%. Net income was up 157.0% year-over-year. Based on available data, Kuros Biosciences AG has been profitable since at least 2015.

is CSBTF profitabledoes CSBTF make a profitCSBTF profitabilityCSBTF profitable company

▸ Source: FMP /income-statement · GAAP · Kuros Biosciences AG · Kuros Biosciences AG SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026